The stock of MiMedx Group Inc (NASDAQ:MDXG) is a huge mover today! About 304,553 shares traded hands. MiMedx Group Inc (NASDAQ:MDXG) has risen 6.28% since March 8, 2016 and is uptrending. It has underperformed by 3.04% the S&P500.
The move comes after 9 months negative chart setup for the $978.45 million company. It was reported on Oct, 11 by Barchart.com. We have $7.90 PT which if reached, will make NASDAQ:MDXG worth $78.28 million less.
Analysts await MiMedx Group Inc (NASDAQ:MDXG) to report earnings on November, 3. They expect $0.05 EPS, down 16.67% or $0.01 from last year’s $0.06 per share. MDXG’s profit will be $5.70 million for 42.95 P/E if the $0.05 EPS becomes a reality. After $0.02 actual EPS reported by MiMedx Group Inc for the previous quarter, Wall Street now forecasts 150.00% EPS growth.
MiMedx Group Inc (NASDAQ:MDXG) Ratings Coverage
Out of 5 analysts covering MiMedx Group (NASDAQ:MDXG), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. MiMedx Group has been the topic of 7 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Needham upgraded the stock to “Strong Buy” rating in Monday, November 16 report. As per Friday, December 18, the company rating was maintained by Canaccord Genuity. The company was upgraded on Friday, October 30 by Northland Capital. The rating was maintained by Lake Street with “Buy” on Tuesday, April 19. The stock has “Overweight” rating given by First Analysis on Wednesday, January 20. The stock has “Buy” rating given by Needham on Wednesday, July 29. The stock of MiMedx Group Inc (NASDAQ:MDXG) earned “Buy” rating by Needham on Wednesday, October 14.
According to Zacks Investment Research, “MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.”
Insitutional Activity: The institutional sentiment decreased to 1.03 in 2016 Q2. Its down 0.49, from 1.52 in 2016Q1. The ratio dived, as 22 funds sold all MiMedx Group Inc shares owned while 49 reduced positions. 21 funds bought stakes while 52 increased positions. They now own 47.18 million shares or 4.50% more from 45.15 million shares in 2016Q1.
Moreover, Smith Asset Mgmt Group L P has 0% invested in MiMedx Group Inc (NASDAQ:MDXG) for 1,069 shares. California Public Employees Retirement holds 59,600 shares or 0% of its portfolio. Wms Prns Ltd Llc has 29,759 shares for 0.03% of their US portfolio. Tudor Et Al last reported 17,800 shares in the company. Murphy Cap accumulated 22,700 shares or 0.03% of the stock. Macquarie has 0% invested in the company for 23,750 shares. Westwood Mgmt Corporation Il accumulated 245,000 shares or 0.37% of the stock. Moreover, Cutter Brokerage has 0.07% invested in MiMedx Group Inc (NASDAQ:MDXG) for 19,150 shares. Massachusetts Services Ma holds 1.14 million shares or 0% of its portfolio. Thompson Inv Management Inc, a Wisconsin-based fund reported 418,665 shares. Teacher Retirement Sys Of Texas holds 0% or 14,361 shares in its portfolio. Morgan Stanley holds 338,916 shares or 0% of its portfolio. Alliancebernstein Lp has 0% invested in the company for 341,200 shares. Rhumbline Advisers has 0% invested in the company for 132,189 shares. Blackrock Japan accumulated 0% or 3,205 shares.
Insider Transactions: Since May 12, 2016, the stock had 4 buys, and 3 selling transactions for $394,659 net activity. Taylor William Charles also sold $219,703 worth of MiMedx Group Inc (NASDAQ:MDXG) on Thursday, July 28. The insider PETIT PARKER H bought $337,000.
More notable recent MiMedx Group Inc (NASDAQ:MDXG) news were published by: Prnewswire.com which released: “MiMedx Announces 2015 Record Results” on February 23, 2016, also Prnewswire.com with their article: “MiMedx Announces Nationwide Launch of New Ambient Temperature Version of OrthoFlo” published on July 25, 2016, Prnewswire.com published: “MiMedx Reaffirms Q3 and Full Year 2016 Guidance” on September 06, 2016. More interesting news about MiMedx Group Inc (NASDAQ:MDXG) were released by: Prnewswire.com and their article: “MiMedx Announces Nationwide Launch of AmnioFillâ„¢” published on September 01, 2016 as well as Prnewswire.com‘s news article titled: “MiMedx Adds New Executive” with publication date: July 07, 2016.
MDXG Company Profile
MiMedx Group, Inc. (MiMedx), incorporated on February 28, 2008, is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Firm operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. The Company’s biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. Elected in advance of delivery through its donor program, a mother delivering a baby through scheduled full-term Caesarean section birth may donate the placenta in lieu of having it discarded as medical waste. The Firm processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.